Bolton LP’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bolton LP’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-50,000	Closed	-$369K	–	211
2015 Q1	$369K	Buy	+50,000	New	+$336K	0.1%	89
2014 Q3	–	Sell	-22,300	Closed	-$150K	–	165
2014 Q2	$150K	Buy	+22,300	New	+$142K	0.02%	120

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CWM

CIBC World Markets New York $20.8B AUM

Bolton LP's NWBO Position: Q2 2015 in Review

Bolton LP sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2015, closing a stake of 50,000 shares — an estimated $369K sold.

Bolton LP first reported a position in NWBO in Q2 2014 and held it in 2 quarters. The position peaked at $369K in Q1 2015. 83 funds tracked by Wall St. Rank hold NWBO as of Q2 2015.

Bolton LP reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2015 after selling out during the quarter.
Bolton LP sold 50,000 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2015, an estimated $369K.
Bolton LP first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 2 quarters.
Bolton LP's Northwest Biotherapeutics, Inc. Common stock position peaked at $369K in Q1 2015.
83 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2015.

Based on Bolton LP's 13F filing for Q2 2015, filed 12 Aug 2015.